Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $0.34 Analyst target: $11.68 Upside: 3385.53%
Actuate Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative treatments for serious diseases, particularly in the oncology space. The company is advancing its proprietary drug candidates through comprehensive clinical trials, addressing significant unmet medical needs to enhance patient outcomes. With a focus on building a robust pipeline of transformative therapeutic solutions, Actuate is positioned to drive strategic growth and deliver substantial value to its investors, solidifying its competitive edge within the biotechnology industry.
See the full interactive analysis & chart →Informational only — not investment advice.